Design, synthesis and antitumor activity of icotinib derivatives

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase (TK) pathway is crucial in non-small-cell lung cancer (NSCLC) pathogenesis.
• Developing inhibitors effective against both wild-type and mutant EGFR remains a significant challenge in NSCLC treatment.

Purpose of the Study:

• To design and synthesize novel icotinib derivatives incorporating a 1,2,3-triazole moiety.
• To evaluate the in vitro antitumor activity of these compounds against NSCLC cells.
• To elucidate the mechanism of action for promising drug candidates.

Main Methods:

• Synthesis of icotinib-1,2,3-triazole derivatives via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC).
• In vitro antitumor activity assessment using CCK-8 assays.
• Mechanistic studies involving apoptosis induction and cell cycle analysis.
• Enzyme inhibition assays to determine EGFR inhibitory potency (IC50).

Main Results:

• Several synthesized icotinib-1,2,3-triazole compounds, notably a7 and a12, exhibited potent in vitro antitumor activity against NSCLC cells with wild-type and mutant EGFR.
• Compounds a7 and a12 were found to induce NSCLC cell death through mitochondrial apoptosis and cell cycle arrest.
• Compound a12 demonstrated significant EGFR inhibitory activity with an IC50 value of 1.49 μM.

Conclusions:

• Icotinib derivatives containing the 1,2,3-triazole moiety are promising candidates for NSCLC therapy.
• Compound a12, a potent EGFR inhibitor, effectively induces apoptosis and cell cycle arrest, representing a potential new anti-NSCLC therapeutic agent.